Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $20.2857.

Several research firms have recently weighed in on ENTA. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, June 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. Finally, Wall Street Zen lowered Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, May 31st.

Institutional Trading of Enanta Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Janus Henderson Group PLC increased its stake in shares of Enanta Pharmaceuticals by 1.5% in the first quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company’s stock valued at $47,717,000 after purchasing an additional 54,396 shares during the period. Farallon Capital Management LLC raised its holdings in shares of Enanta Pharmaceuticals by 30.6% during the fourth quarter. Farallon Capital Management LLC now owns 2,772,262 shares of the biotechnology company’s stock valued at $43,719,000 after buying an additional 650,000 shares during the last quarter. Krensavage Asset Management LLC boosted its position in shares of Enanta Pharmaceuticals by 30.8% during the fourth quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock worth $43,626,000 after buying an additional 651,946 shares during the period. Millennium Management LLC boosted its position in shares of Enanta Pharmaceuticals by 50.2% during the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after buying an additional 449,945 shares during the period. Finally, Spruce Street Capital LP grew its holdings in Enanta Pharmaceuticals by 139.3% in the 1st quarter. Spruce Street Capital LP now owns 932,598 shares of the biotechnology company’s stock worth $11,779,000 after buying an additional 542,911 shares in the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Price Performance

Shares of NASDAQ ENTA opened at $13.22 on Thursday. Enanta Pharmaceuticals has a 1-year low of $6.45 and a 1-year high of $17.15. The company has a market capitalization of $384.44 million, a price-to-earnings ratio of -5.10 and a beta of 0.98. The business has a 50-day moving average of $13.07 and a 200-day moving average of $13.41.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.01. The business had revenue of $17.16 million during the quarter, compared to analyst estimates of $17.03 million. Enanta Pharmaceuticals had a negative net margin of 89.56% and a negative return on equity of 64.04%. Research analysts expect that Enanta Pharmaceuticals will post -1.79 EPS for the current fiscal year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct?acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.